Medicare GLP-1 Bridge 2027: What Happens After the Program Ends?
Have questions about your Medicare coverage? Talk with a DevotedDOc healthcare provider.
The Medicare GLP-1 Bridge Program is currently scheduled to end on December 31, 2027. Since the program expanded access to medications like Zepbound, Wegovy, and Foundayo for eligible Medicare beneficiaries, many people are now asking what happens when the program expires and whether Medicare will continue to cover these weight-loss medications.
At this time, the answer is not entirely clear. The program has a defined end date. However, the Centers for Medicare & Medicaid Services (CMS) has not announced whether it will extend the program, replace it, or let it end as scheduled. As a result, the future of Medicare GLP-1 coverage for obesity remains uncertain.
This article explains what CMS has announced so far, why the Medicare GLP-1 Bridge Program was created, how it relates to the proposed BALANCE Model, and what beneficiaries should know as the end of 2027 approaches. Rather than speculating about future policy changes, we’ll focus on the current guidance available from CMS and other authoritative sources.
If you’re unfamiliar with how the program works today, our guide to the Medicare GLP-1 Bridge Program explains the current eligibility requirements, covered medications, and enrollment process.
When Does the Medicare GLP-1 Bridge Program End?
Under current CMS guidance, the Medicare GLP-1 Bridge Program is scheduled to remain available through December 31, 2027.
The program launched on July 1, 2026, as a temporary nationwide demonstration. It gives eligible Medicare beneficiaries access to select GLP-1 medications for chronic weight management at a flat monthly copayment. CMS initially planned to end the demonstration after 2026. The agency later extended it through the end of 2027 and delayed a longer-term replacement model.
Unless CMS announces additional changes, the current GLP-1 Bridge Program end date remains December 31, 2027.
Why Does the Medicare GLP-1 Bridge Program End in 2027?
The Medicare GLP-1 Bridge Program was never intended to be a permanent Medicare benefit. Instead, CMS established it as a temporary demonstration program to expand access to certain weight loss medications. The program also gathers real-world information about how beneficiaries use these therapies and how they affect Medicare spending.
The program also gives CMS additional time to evaluate broader approaches to Medicare obesity treatment coverage. This helps the agency make long-term policy decisions. During the demonstration, eligible beneficiaries can receive covered GLP-1 medications outside the standard Medicare Part D benefit. CMS administers these prescriptions through a separate claims process.
This temporary structure is one reason Medicare GLP-1 coverage changes remain possible in the future. Demonstration programs are designed to test new approaches before policymakers decide whether to modify, expand, replace, or discontinue them. As of now, however, CMS has not announced what will happen once the current demonstration reaches its scheduled end date.
What Happened to the BALANCE Model?
When CMS first announced the Medicare GLP-1 Bridge Program, it was intended to serve as a short-term solution before a larger demonstration called the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model began in 2027.
CMS designed the BALANCE Model to expand access to GLP-1 medications. The model also encourages healthy lifestyle changes through participating Medicare Part D plans and state Medicaid programs. Under the original proposal, eligible beneficiaries would receive covered GLP-1 medications. They would also receive lifestyle support programs to improve long-term treatment success.
However, CMS later announced that it would delay implementation of the BALANCE Model for Medicare Part D indefinitely. Instead, the agency extended the Medicare GLP-1 Bridge Program through December 31, 2027, allowing additional time to collect utilization data and evaluate future policy options.
According to CMS and KFF, limited participation from Medicare Part D plan sponsors contributed to the delay. They also reported that additional time would allow for a smoother transition before launching a larger long-term model.
As of now, CMS has not announced a new implementation date for the BALANCE Model in Medicare Part D.
Will Medicare Still Cover GLP-1 Medications After 2027?
This is one of the biggest questions beneficiaries are asking, but there is currently no definitive answer.
If CMS does not introduce a new Medicare demonstration or Congress does not change the law, beneficiaries using GLP-1 medications solely for chronic weight management may return to existing Medicare coverage rules. Under current law, Medicare generally excludes medications used only to treat obesity outside the temporary Bridge Program.
However, this does not mean beneficiaries will automatically lose access to every GLP-1 medication.
Medicare Part D would continue covering medications prescribed for FDA-approved indications. These may include type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea when applicable. Those prescriptions would follow the standard Part D coverage process rather than the Bridge Program. These existing coverage pathways remain separate from the temporary demonstration.
Because CMS has not announced whether the Bridge Program will be extended again or replaced with another demonstration, the future of Medicare GLP-1 coverage remains uncertain. Beneficiaries should watch for future CMS announcements rather than assume coverage will either continue unchanged or end completely.
What Could Happen if the Bridge Program Ends?
While no one can predict future Medicare policy, CMS has not identified a permanent replacement for the Medicare GLP-1 Bridge Program.
If the program ends as scheduled and CMS does not create a new coverage pathway, beneficiaries who rely on the Bridge Program for GLP-1 medications may need to return to standard Medicare coverage rules. KFF notes that, under this scenario, some beneficiaries could lose access to Bridge coverage for obesity treatment unless CMS implements the BALANCE Model or establishes another coverage mechanism.
At the same time, beneficiaries whose GLP-1 medications qualify under existing Medicare Part D coverage for other FDA-approved indications would continue using their regular Part D benefits, as those prescriptions are not dependent on the Bridge Program.
Because these policy decisions have not yet been made, beneficiaries should avoid making assumptions based on speculation. Future Medicare prescription drug updates from CMS will provide the most reliable information about any changes to GLP-1 coverage after 2027.
What Should Current Beneficiaries Do Before 2027 Ends?
Although Medicare GLP-1 Bridge 2027 is scheduled to end on December 31, 2027, there is no need to make immediate changes based on uncertainty alone. The program remains active, and eligible beneficiaries can continue receiving covered medications while CMS evaluates future policy options.
If you are currently using a GLP-1 medication through the Bridge Program, consider taking these practical steps as 2027 approaches.
Stay informed about Medicare updates
Because the future of the program has not yet been announced, it’s important to monitor official CMS and Medicare communications for any policy changes.
CMS may provide additional guidance before the end of 2027 regarding:
- Extensions of the Medicare GLP-1 Bridge Program
- Implementation of the BALANCE Model
- New Medicare obesity treatment policies
- Changes to Medicare prescription drug coverage
Following official announcements can help you understand any future changes before they affect your treatment.
Continue working with your healthcare provider
Do not stop taking your medication simply because the current demonstration has an end date.
If you are benefiting from treatment, continue attending follow-up appointments and discussing your progress with your healthcare provider. They can monitor your response to therapy, adjust your treatment plan when appropriate, and help you understand any future Medicare coverage changes that may affect your prescription.
If you’re considering starting treatment before the end of the demonstration, our online Zepbound prescription service can help determine whether Zepbound is an appropriate option based on your medical history and treatment goals.
Keep your coverage documentation current
Even while the Bridge Program remains active, maintaining accurate documentation can help avoid delays if prior authorization renewals or future coverage changes occur.
Your healthcare provider may need to verify your eligibility, document your diagnosis, and submit any required paperwork as part of your ongoing treatment.
If you’d like to learn more about the approval process, our guide to prior authorization requirements explains how healthcare providers submit documentation and what information Medicare may request.
Frequently Asked Questions
Under current CMS guidance, the Medicare GLP-1 Bridge Program is scheduled to end on December 31, 2027. CMS has not announced whether it will extend the program or introduce a permanent replacement.
At this time, CMS has not announced whether Zepbound Medicare coverage in 2027 will continue beyond the scheduled end of the Bridge Program. If no new coverage pathway is established, Medicare coverage for weight management may return to the existing rules. However, no final decision has been announced.
The BALANCE Model is a proposed CMS demonstration that aims to expand access to GLP-1 medications and lifestyle support through participating Medicare Part D plans and Medicaid programs. CMS has delayed its Medicare Part D implementation indefinitely while the agency collects more data through the Medicare GLP-1 Bridge Program.
No. If you’re currently receiving treatment through the Medicare GLP-1 Bridge Program, continue taking your medication as prescribed and discuss any questions with your healthcare provider. There is currently no CMS guidance recommending that beneficiaries discontinue treatment because of the program’s scheduled end date.
The best sources are official CMS and Medicare announcements. As new policies become available, your healthcare provider can also help explain how any Medicare GLP-1 coverage changes may affect your treatment options.
Plan Ahead for Future Medicare Coverage Changes
Although the future of the Medicare GLP-1 Bridge Program after 2027 remains uncertain, you don’t have to navigate potential coverage changes alone. Staying informed and maintaining regular follow-up with your healthcare provider can help you prepare for any updates CMS announces in the future.
At DevotedDOc, we help patients evaluate GLP-1 treatment options, understand Medicare coverage requirements, and develop personalized weight management plans based on their health goals. Learn more about our medical weight loss program to discuss your treatment options with a healthcare provider.